Drug
Asparaginase erwinia chrysanthemi clinical trials
Also written Erwinase, JZP 458, Crisantaspase and Rylaze.
- studies test it
- 21
- open now
- 3
- in phase 3
- 6
- first study started
- 1997
Keep track of what changes. Save the asparaginase erwinia chrysanthemi studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Other names
Combined with it in one product
Studies by the year they started
21 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2000 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 1 |
| 2012 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 11
- Phase 3
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 18
St. Jude Children's Research Hospital (9) · Jazz Pharmaceuticals (3) · M.D. Anderson Cancer Center (2) · City of Hope Medical Center (2) · Children's Oncology Group (1) · Ashkan Emadi (1) · Baylor College of Medicine (1) · University of Washington (1)
Often tested with
Tested in the same studies.
Etoposide (9) · Cytarabine (8) · Methotrexate (7) · Dexamethasone (7) · Pegaspargase (7) · Cyclophosphamide (7) · Mercaptopurine (7) · Vincristine (7)
Studies
Open first, then newest update. How each study uses asparaginase erwinia chrysanthemi is read from its arms, and is right about nine times in ten.
Testing it · 21
- Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT07133997Written as Asparaginase Erwinia chrysanthemi
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingPhase 2City of Hope Medical CenterNCT06918431Written as Asparaginase Erwinia chrysanthemi
- UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLRecruitingEarly Phase 1Baylor College of MedicineNCT07059975Written as Asparaginase Erwinia Chrysanthemi (recombinant)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaSuspendedPhase 2University of WashingtonNCT06738368Written as Asparaginase Erwinia chrysanthemi
- Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down SyndromeActive, not recruitingPhase 3Children's Oncology GroupNCT02521493Written as Asparaginase Erwinia chrysanthemi
- Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) IActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT02553460Written as Asparaginase Erwinia Chrysanthemi
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingPhase 2/3St. Jude Children's Research HospitalNCT03117751Written as Erwinase®
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT03164057Written as Erwinia asparaginase
- An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)CompletedPhase 2/3Jazz PharmaceuticalsNCT04145531Written as IV JZP-458
- Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaCompletedPhase 3St. Jude Children's Research HospitalNCT00549848Written as Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine
- NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic LymphomaCompletedPhase 2St. Jude Children's Research HospitalNCT01451515Written as Erwinia asparaginase
- A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase TherapyCompletedPhase 2Jazz PharmaceuticalsNCT01643408Written as asparaginase Erwinia chrysanthemi
- Therapy for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaCompletedPhase 3St. Jude Children's Research HospitalNCT00137111Written as Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase
- Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)TerminatedPhase 1Therapeutic Advances in Childhood Leukemia ConsortiumNCT00928200Written as Erwinase
- Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic MalignanciesWithdrawnPhase 2M.D. Anderson Cancer CenterNCT02718755Written as Erwinase
- 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)CompletedPhase 1Ashkan EmadiNCT02283190Written as Erwinase
- Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedPhase 2St. Jude Children's Research HospitalNCT00186875Written as L-asparaginase, erwinia asparaginase
- Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins LymphomaCompletedPhase 1St. Jude Children's Research HospitalNCT00693602Written as Erwinase
- An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)WithdrawnPhase 2Jazz PharmaceuticalsNCT02150928Written as Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
- Erwinase Study in Patients With Acute Lymphoblastic LeukemiaCompletedNot applicableM.D. Anderson Cancer CenterNCT00506597Written as Erwinase
See all 21 studies that test asparaginase erwinia chrysanthemi →
Given in every arm · 14 — asparaginase erwinia chrysanthemi is usual care beside what is tested
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Asparaginase Erwinia chrysanthemi
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingPhase 3Children's Oncology GroupNCT04293562Written as Asparaginase Erwinia chrysanthemi
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT04546399Written as Asparaginase Erwinia chrysanthemi
- Venetoclax Basket Trial for High Risk Hematologic MalignanciesRecruitingPhase 1Andrew E. Place, MDNCT05292664Written as Erwinia asparaginase
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017RecruitingPhase 3Martin SchrappeNCT03643276Written as Erwinase
- Ma-Spore ALL 2020 StudyRecruitingPhase 2National University Hospital, SingaporeNCT06336395Written as Erwinase
- Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT05192889Written as Erwinia asparaginase
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03914625Written as Asparaginase Erwinia chrysanthemi
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2Children's Oncology GroupNCT02981628Written as Asparaginase Erwinia chrysanthemi
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsActive, not recruitingPhase 3Dana-Farber Cancer InstituteNCT03020030Written as Erwinia asparaginase
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaCompletedPhase 2Incyte CorporationNCT02723994Written as Asparaginase Erwinia Chrysanthemi
- Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaTerminatedPhase 2SanofiNCT03860844Written as L - Asparaginase (Erwinase)
- AflacLL1901 (CHOA-AML)TerminatedPhase 2Emory UniversityNCT04326439Written as Erwinase
- Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic MalignanciesTerminatedPhase 2St. Jude Children's Research HospitalNCT02419755Written as Erwinia L-Asparaginase
As the comparator · 1 — what is tested is compared with asparaginase erwinia chrysanthemi
Codes
What other systems call asparaginase erwinia chrysanthemi · ClinicalTrials.gg INT001667
- MeSH (NLM) C000718243asparaginase erwinia chrysanthemiConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) D733ET3F9OASPARAGINASE ERWINIA CHRYSANTHEMIConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64260Asparaginase Erwinia chrysanthemiOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718243 | asparaginase erwinia chrysanthemi | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D733ET3F9O | ASPARAGINASE ERWINIA CHRYSANTHEMI | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64260 | Asparaginase Erwinia chrysanthemi | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.